Stocktoria
Lucid Diagnostics Inc. LUCD
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-10-14
Lucid Diagnostics Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 | — |
| Gross profit | — | — | — | $377,000 | $500,000 | — |
| R&D expense | $5.7M | $6.0M | $7.3M | $11.3M | $9.3M | $5.4M |
| SG&A expense | — | — | — | — | $21,000 | $7,000 |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M | -$8.3M |
| Interest expense | — | $26,000 | $416,000 | $8,000 | — | — |
| Income tax | $0 | $0 | — | — | — | — |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M | -$8.3M |
| EPS (diluted) | — | $-1.05 | $-1.26 | $-1.55 | — | — |
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M | -$5.6M |
| Free cash flow | -$46.7M | -$44.4M | — | -$32.9M | -$18.5M | — |
| Cash & equivalents | — | $22.4M | $18.9M | $22.5M | $53.7M | — |
| Inventory | $353,000 | $341,000 | $278,000 | $111,000 | — | — |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M | $2.2M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M | $15.7M |
| Shareholders' equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M | -$13.5M |
Growth · year-over-year · Revenue CAGR 75.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +8.3% | +79.0% | +544.0% | -24.6% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.